

1 *Type of the Paper: Review*

2

3 **Title: Neuropsychiatric Borreliosis/Tick-Borne Disease:**
4 **An Overview**

5

6 **Author: Robert C Bransfield**

7 **Affiliation: Department of Psychiatry, Rutgers-Robert Wood Johnson**
8 **Medical School, Piscataway, NJ, USA; bransfield@comcast.net**

9

10 Correspondence: bransfield@comcast.net ; Tel: +1-732-741-3263

11

12 Robert C Bransfield, MD, DLFAPA

13 225 Highway 35, Ste 107

14 Red Bank, NJ, USA 07701

15 Fax: 732-741-5308

16

17

18

19

20

21

22

23

24

25

26

27 **Neuropsychiatric Borreliosis/Tick-Borne Disease: An Overview**

28 **Abstract**

29 There is increasing evidence and recognition that Lyme borreliosis, and other associated
30 tick-borne diseases (LB/TBD) cause mental symptoms. Data was drawn from databases,
31 search engines and clinical experience to review current information on LB/TBD. LB/TBD
32 infections cause immune and metabolic effects that result in a gradually developing
33 spectrum of neuropsychiatric symptoms, usually presenting with significant comorbidity
34 and may include developmental disorders, autism spectrum disorders, schizoaffective
35 disorders, bipolar disorder, depression, anxiety disorders (panic disorder, social anxiety
36 disorder, generalized anxiety disorder, posttraumatic stress disorder, intrusive symptoms),
37 eating disorders, decreased libido, sleep disorders, addiction, opioid addiction, cognitive
38 impairments, dementia, seizure disorders, suicide, violence, anhedonia, depersonalization,
39 dissociative episodes, derealization and other impairments. Screening assessment followed
40 by a comprehensive psychiatric clinical exam relevant to patient's complaints and findings
41 with a thorough history, mental status exam, review of systems, neurological exam,
42 physical exam, a knowledgeable interpretation of laboratory findings, pattern recognition
43 and clinical judgment facilitate diagnosis. Psychotropics and antibiotics may help improve
44 functioning and prevent further disease progression. Awareness of the association between
45 LB/TBD and neuropsychiatric impairments and studies of their prevalence in
46 neuropsychiatric conditions can improve understanding of the causes of mental illness and
47 violence and result in more effective prevention, diagnosis and treatment.

48 **Keywords:** Lyme disease; *Borrelia burgdorferi*; tickborne diseases; persistent infection;
49 treatment; assessment; depression; anxiety; sleep disorders; opioid addiction

50 **Background**

51 Lyme disease is caused by *Borrelia burgdorferi*, other *Borrelia* species and other tick-
52 borne and opportunistic infections may be present as well [1]. There is increasing evidence
53 and recognition that Lyme borreliosis and other associated tick-borne diseases (LB/TBD)
54 cause mental symptoms. Currently there are over 400 peer-reviewed articles addressing
55 different aspects of neuropsychiatric symptoms caused by LB/TBD [2].

56 Although mental illnesses have been categorized based upon symptoms and syndromes
57 since 1952 by the American Psychiatric Association in Diagnostic and Statistical Manuals
58 (DSM), this categorization does not address the actual cause of mental illnesses [3]. Mental
59 illness is associated with an impairment of adaptive capabilities and the causes of these
60 impairments need to be viewed from perspectives of the multisystem interaction of multiple
61 contributors and deterrents and how this impacts pathological process that progresses over
62 time. Less complex and better understood disease models consist of well-defined and more
63 limited causes, pathophysiology and clinical presentations. The diseases that are more
64 challenging to understand consist of multiple contributors, multiple pathophysiological
65 pathways and multiple disease presentations.

66 Several developments have helped our understanding of complex disease—evolutionary
67 medicine, the better recognition of the role of chronic infections in chronic disease and
68 attention to the human microbiome. Evolutionary or Darwinian medicine, recognizes a
69 significant cause of disease is trauma from competing organisms, such as microbes [4]. The
70 Center for Disease and Prevention of the United States (CDC) has stated that clinicians and
71 policymakers must recognize that many chronic diseases may indeed have infectious
72 origins [5]. The National Institute of Health Human Microbiome Project recognizes
73 bacterial cells outnumber human cells by 10 to 1, humans depend on their microbiome and
74 a person should really be considered a superorganism [6]. Although the Infectome is
75 beneficial to health in many ways, there are thousands of articles demonstrating a causal
76 association between infections and mental illness, especially viral, venereal and vector-
77 borne diseases [2].

78 When mental hospitals were filled with syphilitic patients everyone recognized infections
79 caused mental illness. After penicillin helped control this epidemic there was a reduced
80 attention to the association between infectious disease and mental illness. Subsequently,
81 attention to evolutionary concepts, the microbiome and psychoimmunology facilitated by
82 microarray testing and further research reactivated attention to the role of infectious
83 contributors to the pathogenesis of mental illness. There are currently over 100 different
84 infectious agents known to cause mental illnesses, including spirochetes, other bacteria,
85 viruses, parasites, protozoa, parasites, yeast, fungi and prion [7,8].

86 One of the contributors to mental illness includes infectious diseases and the immune
87 reactions to them. A number of infections, including LB/TBD have evolved as particularly
88 significant models explaining the association between infections and the development of
89 mental illness. Although there have been some prior neuropsychiatric LB/TBD general
90 review articles, no other neuropsychiatric LB/TBD journal articles have been published
91 recently and a more current review was needed. [7,9,10,11].

92 **Materials and Method**

93 Data for this article was drawn from a database maintained by the author that includes all
94 the journal articles addressing LB/TBD and their association with neuropsychiatric
95 symptoms, other articles and presentations on the subject and experience from treating
96 thousands of LB/TBD patients over decades. These articles were reviewed to look for
97 current information on LB/TBD and neuropsychiatric symptoms. The medical literature
98 was also reviewed with PubMed and Google Scholar searches for additional information in
99 a number of categories which included pathophysiology, clinical presentations, assessment
100 and treatment. Particular attention was given to valid research articles that calculated the
101 prevalence of acquired neuropsychiatric findings in LB/TBD patients post infection. When
102 statistics were drawn from the Aggressiveness, Violence, Homicidality, Homicide and
103 Lyme Disease article; the non-homicidal group was used unless otherwise stated [12].

104

105

106 **Results**

107 **Pathophysiology**

108 Many infections are associated with an early inflammatory reaction followed by adaptive
109 immunity and a resolution of symptoms, but in some chronic infections that evade and
110 suppress the immune system, such as *B. burgdorferi* and other *Borrelia*, inflammation can
111 persist without adaptive immunity, autoimmune symptoms may occur, and reinfections are
112 common. [2,13,14,15,16,17].

113 There are three basic types of *B. burgdorferi* infections causing neuropsychiatric
114 symptoms—the meningovascular form associated with cerebrovascular infarcts; infection
115 within the central nervous system (CNS) which is the atrophic form of Lyme
116 meningoencephalitis and is associated with cortical atrophy, gliosis and dementia and the
117 third is infection outside the CNS causing immune and other effects within the CNS that
118 contribute to neuropsychiatric symptoms. A LB/TBD patient with neuropsychiatric
119 symptoms may have one or more than one of these three types of infections [18,19,20].
120 Although some injury to the host is a result of the direct action of the parasite upon the
121 host, more often the immune reaction to the infection that results in symptoms in the host.
122 Articles have described how the immune and psychoimmune response to *B. burgdorferi*
123 have resulted in psychiatric symptoms. Immune mediated effects are significant
124 contributors to the pathophysiological processes and disease progression. These immune
125 effects include persistent inflammation with cytokine effects and autoimmunity and both of
126 these mechanisms may occur at the same time in persistent infections [2,21].

127 Lyme disease has been associated with the proinflammatory cytokines interleukin-6,
128 interleukin-8, interleukin-12, interleukin-18 and interferon-gamma, the chemokines
129 CXCL12, CXCL13 and CCL19 and increased levels of proinflammatory lipoproteins
130 [20,22,23,24]. *B. burgdorferi* surface glycolipids and flagella antibodies appear to elicit
131 anti-neuronal antibodies and anti-neuronal antibodies and *B. burgdorferi* lipoproteins can
132 disseminate from the periphery to inflame the brain” and these persistent inflammatory
133 effects are associated with neurodegenerative changes [20]. Persistent inflammation is also
134 associated with metabolic changes provoked by these immune reactions and include
135 oxidative stress, excitotoxicity, changes in homocysteine metabolism, mitochondrial
136 dysfunction, altered tryptophan catabolism, decreased serotonin and increased quinolinic
137 acid [20]. The presence of chronic inflammation is associated with increased
138 proinflammatory cytokines which increase levels of indoleamine 2,3-dioxygenase, which
139 converts tryptophan into quinolinic acid which is a neurotoxic metabolite and is a known
140 agonist of N-methyl-D-aspartate synaptic function and increases depressive, cognitive and
141 other symptoms [25]. Quinolinic acid is significantly elevated in cerebral spinal fluid in *B.*
142 *burgdorferi* infections, more significantly in patients with CNS inflammation than in
143 encephalopathy and correlates with the severity of CNS symptoms, including depression
144 [23,26].

145 Besides *B. burgdorferi*, other known and unknown interactive tick-borne diseases such as
146 *Babesia*, *Bartonella*, *Ehrlichia*, and *Mycoplasma* have immune and metabolic effects that
147 further add to the complexity of the pathophysiology of tick-borne infections

148 [27,28,29,30,31]. Opportunistic coinfections which may or may not be tickborne pathogens
149 may also add to the complex interactive infectious process [32].

150 Some chronic symptoms are associated with injury and resulting dysfunction from past
151 infection(s), other chronic symptoms are associated with chronic persistent or latent and
152 relapsing infections [20]. In spite of considerable evidence supporting persistent infection
153 with LB/TBD, some speculate that disease progression is caused by some continuing self-
154 perpetuating post-infectious pathological process, although no viable mechanism has ever
155 previously been demonstrated. However, what starts a disease process may be different
156 from what causes further disease progression. Non-restorative sleep and chronic
157 unremitting stress appear to play a significant role in disease progression in LB/TBD. In
158 one study all Lyme disease patients studied had acquired sleep disorders [33]. Both non-
159 restorative sleep and the chronic unremitting stress seen in these chronically ill patients
160 contribute to disease perpetuation and progression and are associated with fatigue,
161 cognitive impairments, decreased regenerative functioning, compromised immunity,
162 decreased resistance to infectious disease and neurodegenerative processes
163 [34,35,36,37,38].

164 **Clinical presentations**

165 It is recognized up to 40% of patients with Lyme disease develop neurologic involvement
166 of either the peripheral or central nervous system. Similar to syphilis, Lyme disease may
167 have a latency period of years before symptoms of late infection emerge. A broad range of
168 psychiatric findings associated with Lyme disease include paranoia, dementia,
169 schizophrenia, bipolar disorder, panic attacks, major depression, anorexia nervosa, and
170 obsessive-compulsive disorder [10].

171 In reviewing multiple articles, it was apparent that each patient can have a unique and
172 variable clinical presentation, however common symptom patterns are seen. Pre-infection
173 most patients were young, quite active and healthy. A LB/TBD infection may have no or
174 minimal effect in some, be severe in some, result in a latent infection in others, have a
175 relapsing and remitting course in others, be slowly progressive in some and be rapidly
176 progressive in others. It may cause a spectrum of multisystem symptoms which may
177 include neuropsychiatric and somatic symptoms that may be initially subtle while
178 becoming more severe with further disease progression. The neuropsychiatric
179 manifestations may be cognitive, emotional, vegetative and behavioral and can be
180 associated with almost any diagnosis in the DSM, but some psychiatric syndromes are more
181 commonly seen than others. Significant psychiatric comorbidity is commonly seen.

182 Infections at different times in the lifespan (congenital, infancy, childhood, adolescence,
183 adulthood, geriatric) has different pathological effects [8,9,10,11,39].

184 Studies have looked at both the presence of LB/TBD in identified psychiatric patients and
185 the emergence of neuropsychiatric symptoms in identified LB/TBD patients after becoming
186 infected. In identified psychiatric patients, a higher prevalence of antibodies to *B.*

187 *burgdorferi* was seen in hospitalized psychiatric patients when compared to matched pairs
188 of healthy subjects (33% vs. 19%) and 80% of children with psychiatric illness referred to a
189 child psychiatrist tested positive for LB/TBD and 74% of children with an onset of bipolar

190 disorder referred to a child psychiatrist tested positive for LB/TBD [40,41]. In identified
191 LB/TBD patients a number of studies have looked at the percentages of different
192 psychiatric findings that emerged post infection. These studies were on patients who were
193 mostly young and healthy pre-infection and studies also identified the same patients prior to
194 infection as a control group [12,42]. The details of these studies shall be discussed further
195 when discussing different disease presentations.

196 The total neuropsychiatric symptoms associated with LB/TBD results in a significant
197 amount of impairment, disability and death [12,42,43,44].

198 **Developmental disorders**

199 Congenital LB/TBD infections can contribute to developmental disorders and
200 neuropsychiatric impairments [45,46,47,48]. Since 1985 there are over 60 references
201 documenting congenital transmission and associated pathological outcomes with LB/TBD
202 [2,49]. The most comprehensive study was a review of 263 cases and included cases of
203 miscarriage, stillbirth, perinatal death, congenital anomalies, systemic illness, early onset
204 fulminant sepsis and later-onset chronic progressive symptoms associated with gestational
205 LB [50].

206 The study most relevant to neuropsychiatric symptoms was an analysis of 102 gestational
207 LB/TBD cases which demonstrated 9% had been diagnosed with autism and 56% with
208 attention deficit disorder in addition to a broad spectrum of multisystem symptoms. Other
209 psychiatric symptoms included irritability or mood swings (54%), anger or rage (23%),
210 anxiety (21%), depression (13%), emotional lability (13%), obsessive compulsive disorder
211 (11%), suicidal thoughts (7%), developmental delays (18%), tic disorders (14%), seizure
212 disorders (11%), involuntary athetoid movements (9%), photophobia (43%), auditory
213 hyperacuity (36%), other sensory hyperacuity (tactile, taste or smell) (23%), poor memory
214 (39%), cognitive impairments (27%), speech delays (21%), reading/writing impairments
215 (19%), articulation impairments (17%), auditory/visual processing impairments (13%),
216 word selectivity impairments (12%), and dyslexia (18%). In the control group of 66
217 mothers with Lyme disease who were treated with antibiotics prior to conception and
218 during the entire pregnancy; all gave birth to normal healthy infants. However, in the
219 control group there were eight pregnancies that resulted in *B. burgdorferi* and/or *Bartonella*
220 *henselae* positive placentas, umbilical cords, and or foreskin remnants. The PCR positive
221 cases were treated successfully with oral antibiotics [51,52].

222 **Autism spectrum disorders**

223 Autism spectrum disorder (ASD) is associated with LB/TBD
224 [7,52,53,54,55,56,57,58,59,60]. ASD results from multiple etiologies with both genetic and
225 environmental contributions, including at least 23 different infections, seven of which are
226 chronic infections (*Babesia*, *Bartonella*, *B. burgdorferi*, *Ehrlichia*, *Human herpesvirus-6*,
227 *Chlamydia pneumoniae* and *Mycoplasma*), and the immune reactions associated with them
228 [7]. The timing of the infection and immune response is critical in determining the
229 pathophysiology. In congenital infections maternal immune reactions to infections appear
230 to adversely affect fetal brain development and possible pathophysiological mechanisms
231 include both autoimmune and inflammatory processes [7,52]. The association between

232 ASD and LB/TBD is often overlooked since 94% of LB/TBD initially tested negative on
233 two tier CDC *B. burgdorferi* surveillance criteria testing, however 92% of LB/TBD patients
234 with ASD had reactivity of the 31 and 34 bands (outer surface protein-A and outer surface
235 protein-B) on Western blot testing which is not reported on many of the commercially
236 available tests for *B. burgdorferi* [61].

237 Treatment of LB/TBD during pregnancy can prevent the development of ASD associated
238 with LB/TBD [51,52]. Another study demonstrated antibiotic treatment can reduce
239 symptoms of ASD associated with LB/TBD [62].

240 States in the United States with the highest prevalence of ASD have the highest prevalence
241 of *B. burgdorferi* and states with the lowest prevalence of ASD have the lowest prevalence
242 of *B. burgdorferi* [62]. Possibly 20-25% of ASD are associated with LB/TBD [7,52].

243 **Schizophrenia and Schizoaffective disorder**

244 Schizophrenia has been associated with a number of infections rather than LB/TBD and
245 evidence drawing an association between LB/TBD is limited [63,64]. There is however a
246 significant geographical correlation between *Ixodes* ticks, LB/TBD and schizophrenia in the
247 United States [65]. When schizophrenia is seen with LB/TBD, it is most commonly
248 schizoaffective disorder [66,67,68,69,70,71,72]. In late stage LD/TBD patients paranoia has
249 a prevalence of 36% and 88% in homicidal patients and hallucinations has a prevalence of
250 42% and 47% in homicidal patients [12].

251 **Bipolar disorder**

252 Bipolar disorder has been associated with a number of infections including LB/TBD
253 [66,73,74]. When bipolar disorder is seen, it is invariably rapid cycling [12]. The
254 prevalence of bipolar illness in LB/TBD is 74% (in children) [75], 47% (mood swings)
255 [76], 28% (homicidal) and 10% [12].

256 **Depression**

257 Depression from LB/TBD can frequently be prevented with early diagnosis and effective
258 treatment [77]. However, when LB/TBD has not been adequately diagnosed and treated, it
259 is a common finding. Studies of different groups with have shown a prevalence of
260 depression of 0% pre-infection [12] and a post-infection incidence of 98% (with homicidal
261 tendencies) [12], 94% [78], 80% (with intrusive symptoms) [79], 76% [12] 64% [76], 51%
262 [80], 50% [81], 37% [82], 37% [83].

263 **Anxiety disorders**

264 Different types of anxiety are caused by LB/TBD. An early manifestation of hyperarousal
265 may present as hypervigilance (54%) [12] and (84%) (homicidal) and/or low frustration
266 tolerance (80%) [42] and 98% (homicidal) [12]. Further symptoms may then include mixed
267 anxiety or different anxiety disorders, such as panic disorder, social anxiety disorder,
268 generalized anxiety disorder, obsessive compulsive disorder and posttraumatic stress
269 disorder. Panic disorder has been associated with LB/TBD [84,85,86,87,88]. Panic disorder
270 has demonstrated a prevalence of 82% (homicidal), 54% (children) [83] and 50% [12].
271 Although no article has ever specifically addressed social anxiety disorder associated with
272 LB/TBD, it is a common finding in patients. The prevalence of social anxiety disorder in
273 LB/TBD was been demonstrated to be 70% [12] and 66% (homicidal) [12]. Generalized

274 anxiety has been associated with LB/TBD and was 50% [42] and 86% (homicidal) [12].
275 Obsessive compulsive disorder has been reported with LB/TBD, can have an autoimmune
276 pathophysiology and can have a very sudden onset [89,90,91]. The Prevalence of obsessive
277 compulsive disorder in LB/TBD was 84% [92], 51% (homicidal) and 32% [12].
278 Posttraumatic stress disorder has been associated with LB/TBD [93,94]. The prevalence of
279 posttraumatic stress disorder was 24% [12] and 36% (homicidal) [12].
280 Intrusive Symptoms are associated with LB/TBD and may be present with obsessive
281 compulsive disorder, posttraumatic disorder or be present without either of these conditions
282 and demonstrated a prevalence of 34% and included aggressiveness in 89%, altered sexual
283 imagery in 18% and 40% had other intrusive symptoms including bizarre and horrific
284 images [79]. In another study intrusive aggressive images were seen in 62% of homicidal
285 LB/TBD patients but in only 16% of non-homicidal LB/TBD patients. Intrusive sexual
286 images were seen in 26% of homicidal LB/TBD patients while they were seen in only 6%
287 of non-homicidal LB/TBD patients [12]. LB/TBD patients with intrusive symptoms also
288 had cognitive impairments (100%), neurological 98%, obsessiveness (89%),
289 depersonalization (87%), depression (80%), low frustration tolerance (80%), explosive
290 anger (73%), suicidal (69%), social isolation (67%), anhedonia (62%), disinhibition (62%),
291 paranoia (49%), hallucinations (42%) and homicidality (31%) [79].

292 **Eating disorders**

293 A number of eating disorders are associated with LB/TBD. Some LB/TBD patients lose
294 weight early in the disease process and later gain weight. Cases of anorexia nervosa,
295 bulimia and excessive weight gain have been reported [10,95,96,97]. In some cases, tick
296 saliva has resulted in food allergies and intolerances [98].

297 **Sleep disorders**

298 Sleep disorders acquired as a result of LB/TBD are quite significant and include insomnia
299 (early, mid, late), non-restorative sleep, restless leg, paroxysmal nocturnal leg movements,
300 sleep apnea (obstructive and central), nightmares, circadian rhythm shift and narcolepsy
301 (with sleep attacks, cataplexy, sleep paralysis and hypnagogic hallucinations).
302 [33,99,100,101,102,103,104,105,106,107]. Poor sleep quality is associated with impaired
303 immunocompetence and contributes to disease progression [108,109]. Studies have
304 demonstrated a prevalence of sleep disorders in LB/TBD patients at 100% [33], 96% [12],
305 92% [110], 82% [78] and 66% [76]. Among homicidal LD/TBD patients 82% had vivid
306 nightmares [12].

307 **Addiction**

308 The prevalence of chronic pain in suicidal LB/TBD patients is 65%, in suicidal and
309 homicidal LB/TBD patients the prevalence is 57% and in LB/TBD patients who are not
310 suicidal or homicidal the prevalence is 35% [42]. Some LB/TBD patients with chronic pain
311 are treated with opioids [111,112]. In addition, the majority of opioid users have a
312 recognized mental illness [113]. However, unrecognized and inadequately treated mental
313 and physical illnesses are also well recognized risk of substance abuse. The prevalence of
314 substance abuse in LB/TBD patients is 33% (homicidal) [12], 28% (suicidal and homicidal)
315 [42] and 10% (not homicidal or suicidal) [12]. Some LB/TBD patients who have been

316 inadequately diagnosed and treated develop impaired dopamine functioning, have
317 significant disease progression and self-medicate their psychiatric symptoms and pain, then
318 become dependent, lose a sense of purpose and engage in drug-seeking behavior with
319 benzodiazepines, hypnotics, alcohol, pain medication and marijuana. Some of these patients
320 then die from overdoses, including, but not limited to opioid overdoses
321 [114,115,116,117,118,119,120]. Also, some LB/TBD are alcohol sensitive (44%) [12] and
322 drug sensitive and can demonstrate toxic symptoms with exposure to minimal substance
323 exposure [120].

324 **Cognitive impairments**

325 Studies with different study designs reported a number of acquired cognitive impairments
326 in LB/TBD patients [121,122,123,124,125,126]. The prevalence of these impairments in
327 LB/TBD patients are encephalopathy (89%), Memory Loss (81%) [82];
328 attention/concentration impairments (77%), memory complaints (65%), mental fatigue
329 (70%), (children) [83]; attention and concentration impairments (77%), memory complaints
330 (65%), mental fatigue (70%), cognitive impairment (92%) [110]; memory loss (63%), poor
331 concentration (60%), difficulty finding words (46%), confusion (44%), inattention (44%),
332 [76]; impairments of reasoning (93%), memory (92%) and attention (91%), with speaking
333 (75%), listening (73%), reading and/or writing (79%) [127]; short-term memory problems
334 (94%), schoolwork deterioration (94%), brain fog (88%), distractibility (82%), word-
335 finding problems (82%), and moderate to severe sensory hyperacusis to sound (58%) and
336 /or light (74%); word-finding problems (79%)(children) [78]; memory impairments (76%),
337 processing impairments (78%), dyslexia symptoms (68%) [12] and among homicidal
338 subjects: impaired capacity for sustained and/or selective attention (98%), auditory
339 hyperacusis (88%), sensory hyperacusis to light, touch, and/or smell (86%), memory
340 impairments, most commonly working memory and short-term memory (98%), processing
341 impairments (94%), dyslexia symptoms (78%), and executive functioning impairments
342 (98%) [12].

343 **Dementia**

344 There are over 60 articles that address the causal association between LB/TBD and
345 dementia [2]. Two of the three basic types of *B. burgdorferi* infections can contribute to a
346 more rapidly developing dementia—the meningovascular form with cerebrovascular
347 infarcts and the atrophic form with meningoencephalitis, cortical atrophy and gliosis. The
348 atrophic form is associated with a more rapidly progressive dementia [128,129,130].
349 Infection outside the CNS causing immune effects within the CNS can be associated with a
350 very slowly progressive dementia [2,20].

351 **Seizure disorders**

352 A number of articles have documented an association between LB/TBD and seizures
353 [131,132,133,134,135]. Seizures have also been documented associated with *Bartonella*
354 [136]. Seizure disorders are more common when there is a lengthy delay in diagnosis and
355 effective treatment. Most commonly the seizures are complex partial seizures with
356 significant postictal confusion and are sometimes referred to psychiatrists because they are
357 misdiagnosed and being “psychogenic” or so called “pseudoseizures.” The prevalence of

358 seizures in homicidal LB/TBD patients is 20% and were mostly complex partial seizures
359 [12].

360 **Suicide and Violence**

361 Suicidality seen in LB/TBD contributes to causing a significant number of previously
362 unexplained suicides and is associated with immune-mediated and metabolic changes
363 resulting in psychiatric and other symptoms which are probably worsened by negative
364 attitudes about LB/TBD from others. Some LD/TBD suicides are associated with being
365 overwhelmed by multiple debilitating symptoms, and others are impulsive, bizarre, and
366 unpredictable. Negative attitudes about LB/TBD from family, friends, doctors, and the
367 health care system also appeared to contribute to suicide risk. By indirect calculations, it is
368 estimated there are possibly over 1,200 LAD suicides in the US per year [42].

369 Although most LD/TBD patients have no aggressiveness tendencies or mild impairments of
370 frustration tolerance and irritability and pose no danger, a lesser number of patients
371 experience explosive anger, a lesser number experience homicidal thoughts and impulses
372 and much lesser number commit homicides. When homicides have occurred, they have been
373 associated with predatory aggression, poor impulse control and psychosis. Since such large
374 numbers are affected by LB/TBD, a very small percent of patients with these impairments
375 can be highly significant. Most aggression with LB/TBD was impulsive, sometimes
376 provoked by intrusive symptoms, sensory stimulation or frustration and the aggressive
377 behavior was invariably bizarre and senseless. LB/TBD and the associated immune,
378 biochemical, neurotransmitter, and neural circuit reactions to them can cause impairments
379 that increase the risk of violence. In late stage LB/TBD the prevalence of suicidality is 43%
380 [42] and 98% in homicidal LB/TBD patients [12].

381 Although many LB/TBD recognized and unrecognized fatalities are associated with
382 suicides, drug overdoses and homicides, there are other LB/TBD fatalities. Fatalities
383 associated with other neuropsychiatric conditions include congenital Lyme infections,
384 Lyme meningitis, symptomatic late Lyme neuroborreliosis, late Lyme neuritis or
385 neuropathy, meningovascular and neuroborreliosis with cerebral infarcts, intracranial
386 aneurysm, late Lyme encephalitis, late Lyme meningo-encephalitis or meningomyelo
387 encephalitis, atrophic form of Lyme meningo-encephalitis with dementia & subacute
388 presenile dementia. Fatalities associated with somatic impairments include Lyme nephritis,
389 Lyme hepatitis, Lyme aortic aneurysm, coronary artery aneurysm, late Lyme endocarditis,
390 Lyme carditis, late Lyme disease of liver and other viscera, late Lyme disease of kidney &
391 ureter and late Lyme disease of bronchus & lung. [43]

392 **Other psychiatric findings**

393 Other psychiatric findings caused by LB/TBD include anhedonia (56%), anhedonia in
394 homicidal patients (86%), exaggerated startle reflex (66%), exaggerated startle reflex in
395 homicidal patients (84%), disinhibition (32%) disinhibition in homicidal patients (84%),
396 nightmares (58%), depersonalization (52%), depersonalization in homicidal patients (71%),
397 dissociative episodes (12%) dissociative episodes in homicidal patients (38%),
398 derealization (24%), derealization in homicidal patients (37%) and decreased libido (44%),
399 abrupt mood swings in homicidal patients (94%), a decline in social functioning in

400 homicidal patients (91%), a decline in school work or work productivity in homicidal
401 patients (90%), marital and/or family problems in homicidal patients (80%) and legal
402 problems in homicidal patients (42%) [12].

403 **Assessment**

404 Screening assessments are advisable when evaluating psychiatric symptoms when the
405 possibility of LB/TBD may be present [8]. Screening questions include:

- 406 • Do you live, vacation or engage in activities in areas that may expose you to ticks?
- 407 • Have family members, neighbors, or the family dog been infected?
- 408 • Is there a history of a tick bite, possibly with a flu-like illness and/or a bull's eye or
409 other rash?
- 410 • Is there a point at which your health declined, followed by a fluctuating progression
411 and development of multi-systemic symptoms, including cognitive, psychiatric,
412 neurological, and somatic symptoms adversely impacting school, social life, family
413 life?
- 414 • Have you ever been treated for Lyme disease, suspected you had Lyme disease but
415 was told it was ruled out?
- 416 • Have antibiotics ever caused a sudden worsening followed by an improvement of
417 symptoms?

418 If the screening assessment increases diagnostic suspicion a further assessment is indicated.
419 LB/TBD is diagnosed just like any other neuropsychiatric condition by a comprehensive
420 psychiatric clinical exam relevant to patient's complaints and findings with a thorough
421 history, mental status exam, review of systems, neurological exam, physical exam, a
422 knowledgeable interpretation of laboratory findings, pattern recognition and clinical
423 judgment. In considering the diagnosis it is important to look for relapsing progressive
424 multi-systemic symptoms, including cognitive, psychiatric, neurological, and somatic
425 symptoms and to remember the greater the multisystemic comorbidity, the greater the
426 likelihood of a condition impacting the entire body such as a complex infectious disease.
427 The presence of a comorbid condition does not rule out the presence of LB/TBD [42,
428 137,138,139].

429 A comprehensive assessment includes an assessment of the following:

- 430 • **Cognitive:** Attention (sustained attention, allocation of attention, distracted by
431 frustration), sensory hyperacusis (auditory, visual, tactile, olfactory); inability to
432 filter sensory input resulting in stimulation overload; memory (working memory,
433 working spatial memory, short-term memory, long-term memory, word retrieval,
434 number retrieval, name recall, facial recognition, procedural memory, geographical
435 memory); processing (slow processing, letter reversals, spelling errors, word
436 substitution errors, number reversals, reading comprehension impairments, auditory
437 comprehension impairments, sound localization impairments, spatial perceptual
438 distortions, optic ataxia, impaired transposition of laterality, left-right confusion,
439 impaired calculation abilities, impaired fluency of speech, stuttering, slurred speech,
440 impaired fluency of writing, impaired handwriting); executive functioning

- 441 (unfocused concentration, brain fog, prioritizing multiple tasks, multitasking, racing
442 thoughts, intrusive thoughts, obsessive thoughts, mental apathy, abstract reasoning
443 impairments, time management impairments)
- 444 • **Imagery:** depersonalization, derealization, capacity for visual imagery, hypnagogic
445 hallucinations, vivid nightmares, illusions (auditory, visual), hallucinations
446 (auditory, especially musical, visual, olfactory, sensory).
 - 447 • **Emotional:** decreased frustration tolerance, abrupt mood swings, hypervigilance,
448 paranoia, anhedonia
 - 449 • **Behavioral:** disinhibition, exaggerated startle reflex, explosive anger, suicidal,
450 homicidal, accident prone, decreased social functioning, decreases school or job
451 productivity, family and marital conflicts, substance abuse, legal difficulties,
452 dissociative episodes, compensatory compulsions, dropping objects, crying spells,
453 self-mutilation
 - 454 • **Psychiatric syndromes:** depression, rapid cycling bipolar illness, panic disorder,
455 obsessive compulsive disorder, social anxiety disorder, generalized anxiety
456 disorder, posttraumatic stress disorder
 - 457 • **Sleep disorders:** non-restorative sleep, early insomnia, middle of night insomnia,
458 early morning insomnia, hypersomnia, loss or reversal of circadian rhythm, restless
459 leg, paroxysmal nocturnal limb movements, sleep apnea (central and/or
460 obstructive), sleep paralysis, hypnagogic hallucinations, sleep attacks, cataplexy,
461 narcolepsy
 - 462 • **Eating disorders:** anorexia, weight loss, emotional overeating, carbohydrate
463 craving, weight gain (with or without increased food intake)
 - 464 • **Sexual:** decreased libido, increased libido, decrease capacity for arousal, decreased
465 capacity for orgasm, altered sexual imagery
 - 466 • **Temperature control:** body temperature fluctuations, flushing, intolerance to heat,
467 intolerance to cold, decreased body temperature, low grade fevers, night sweats,
468 chills
 - 469 • **Headaches:** cervical radiculopathy, migraine, thunderclap, tension, cluster, sinus,
470 scalp tenderness, temporal mandibular joint, coital cephalgia
 - 471 • **Cranial nerves:** I: loss of smell, altered taste; II/eye: blurred vision, photophobia,
472 intolerance of fluorescent or flickering light, floaters, flashes, conjunctivitis, eye
473 pain, dry eyes, blind spots, night blindness, peripheral shadows, panopsia,
474 papilledema, iritis, uveitis, optic neuritis; II, IV, VI: double vision, eye drifts when
475 tired, ptosis; V: sensory loss and/or pain in any of the three branches on either side;
476 VII: Bell's Palsy; VIII: tinnitus, hearing loss, dizziness, vertigo, motion sickness,
477 Tulio's sign, mal de débarquement; IX, X: episodic loss of speech, choking on food,
478 difficulty swallowing; XI: sternocleidomastoid, trapezius pain and/or weakness;
479 XII: tongue deviates to side
 - 480 • **Seizures:** complex partial, grand mal

- 481 • **Neuropathy:** numbness, tingling, sensory loss, burning, crawling sensation
 482 (formication), static electricity sensation, stabbing sensation, weakness
- 483 • **Other neurological:** fatigue, tremor, twitching, muscle tightness, myoclonic jerks,
 484 tics, Tourette's, ataxia, spasticity, meningismus, disc disease, positive Romberg,
 485 postural tachycardia syndrome (POTS), ortho static hypotension, gait disturbances,
 486 spinal cord signs, gait disturbances, white matter lesions, sensation of vibration
- 487 • **Musculoskeletal:** Joint pain, migratory joint pain, swelling, tightness, crepitations,
 488 neck and back discomfort; periostitis and bone tenderness of tibia, ribs, iliac crest,
 489 sternum, clavicle; epicondylitis; plantar fasciitis, foot tenderness; fibromyalgia;
 490 myalgia, costochondritis (ear, nose, costochondral junctions, xyphoid); tendonitis;
 491 carpal tunnel syndrome
- 492 • **Cardiac:** chest pain, heart block, irregular heart rate, mitral valve prolapse, racing
 493 pulse, POTS, pericarditis, cardiomyopathy, murmur, hypertension, hypertensive
 494 crisis
- 495 • **Pulmonary/upper respiratory:** shortness of breath, air hunger, cough, sore throats,
 496 swollen glands, asthma
- 497 • **Gastrointestinal:** Reflux, irritable gut, nervous stomach, irritable bowel, abdominal
 498 bloating, reduced gastrointestinal motility, gastroparesis, cholecystitis, gall stones
- 499 • **Genitourinary:** Irregular periods, genital pain, breast tenderness, sexual
 500 dysfunction, irritable bladder, interstitial cystitis, urinary incontinence
- 501 • **GU:** Spastic bladder, testicular pain/pelvic pain, menstrual irregularity, sexual
 502 dysfunction, decreased libido.
- 503 • **Immune:** fevers, sweats, chills
- 504 • **Other:** alcohol intolerance, hair loss, thyroid disease, adrenal insufficiency,
 505 hypoglycemia, ankle edema, tooth pain, periodontal disease, nose bleeds,
 506 ecchymoses, splenomegaly, multiple chemical sensitivities, allergies,
 507 lymphocytoma, stria, acrodermatitis chronicum atrophicans

508 The more common symptoms seen in LB/TBD include poor attention span, being easily
 509 distracted by frustration, sensory hypersensitivity causing patients to feel overwhelmed,
 510 poor short-term memory, dyslexia symptoms, slow processing, executive dysfunction, brain
 511 fog, poor time management, depersonalization, intrusive images and thoughts, musical
 512 hallucinations, low frustration tolerance, abrupt mood swings, impulsivity, paranoia,
 513 explosive anger, suicidality, anhedonia, decreased productivity, depression, long duration
 514 panic attacks, social anxiety, generalized anxiety, obsessiveness, non-restorative sleep,
 515 appetite disturbances, decreased libido, headaches, cranial nerve symptoms, neuropathy,
 516 autonomic nervous system symptoms, musculoskeletal symptoms, gastrointestinal
 517 symptoms, genitourinary symptoms, cardiovascular symptoms, fatigue, chronic pain and
 518 alcohol intolerance [12,39,42,137]

519 After an adequate clinical assessment is performed, laboratory testing with proper
 520 interpretation may add to the assessment. It is important to remember that no test can rule

521 out the possibility of LB/TBD [140,141]. The differential diagnosis is complex but the
522 more common differential diagnosis includes other chronic systemic conditions and
523 infections, since many of the symptoms and syndromes seen with LB/TBD may overlap
524 with conditions other than LB/TBD [142].

525 If an inadequate clinical exam is performed it can result in viewing the symptoms as being
526 vague and subjective. Caution must be used in considering the symptoms as having a
527 psychogenic basis, such as hypochondriasis, somatization disorder, or a psychosomatic
528 condition. Both hypochondriasis and psychosomatic illnesses begin in childhood and are
529 lifelong conditions with a psychodynamic explanation and vary in intensity depending upon
530 life stressors. If a complex, progressive multisystemic illness begins in a person who was
531 reasonably healthy throughout most of their life, the likelihood that this is psychosomatic or
532 has some other psychogenic basis is very remote. Another diagnostic error by clinicians
533 who lack psychiatric diagnostic capability is to consider these symptoms as being so called
534 “medically unexplained symptoms” or “bodily distress syndrome.” The concept of
535 medically unexplained symptoms was removed from DMS-5 since these symptoms were
536 often instead medically unexamined symptoms. [3]

537 **Treatment**

538 All treatments are a risk vs. benefit decision and inadequately treated LB/TBD can result in
539 a broad spectrum of risks as previously described. A complex, chronic, LB/TBD patient
540 may have a multitude of different symptoms. What causes a condition may be different
541 from what perpetuates a condition. It is best to make a list with the patient ranking which
542 symptoms are the most severe and most impede recovery and consider how the symptoms
543 interact with each other. This will determine the sequence of initiating different treatment
544 strategies. One major question is considering whether antibiotic or symptomatic treatment
545 has higher priority. When a patient has been treated with just antibiotics and has not
546 adequately responded, consider treating the symptoms with psychotropics or other
547 symptomatic treatments. When a patient has been treated with just psychotropics and has
548 not adequately responded, consider treating the symptoms with antibiotics [143,144]. When
549 a patient is treatment resistant consider both symptomatic and antibiotic treatment.

550 Although each patient may have a unique presentation, the most common symptoms
551 impeding recovery are non-restorative sleep and/or chronic unremitting stress. Both are
552 associated with a high allostatic load and compromised immune functioning. Non-
553 restorative sleep is often associated with the terrible triad which consists of non-restorative
554 sleep, fatigue and cognitive impairments [143].

555 Chronic unremitting stress is often associated with hyperarousal and emotional symptoms
556 such as depression, anxiety, depersonalization, mood swings and psychosis. Other
557 symptoms that may be a focus of treatment may include chronic pain (headaches,
558 neuropathy, radiculopathy, musculoskeletal, etc.), complex partial seizures, dysautonomia,
559 gastrointestinal symptoms, genitourinary symptoms, substance abuse and addiction [143].
560 Regardless of the debate surrounding the chronicity of infection and the chronicity of
561 symptoms with LD/TBD, treating psychiatric symptoms with psychotropics can prevent

562 and sometimes reverse progression of illness. Since non-restorative sleep and chronic
563 unremitting stress contribute to disease progression, impaired functioning and compromised
564 immune functioning; improvement in these areas can prevent disease progression, improve
565 functioning and improve immune functioning and resistance to infection. Successful
566 psychiatric management can sometimes result in reduction of infection and successful
567 reduction of infection can sometimes result in reducing psychiatric symptoms and reducing
568 the need for psychotropics [143].

569 No drugs are specifically approved by the Federal Drug Administration (FDA) for the
570 treatment of psychiatric symptoms associated with LB/TBD. Since LB/TBD can be
571 associated with the full spectrum of psychiatric symptoms, all psychotropic are sometimes
572 used and these medications may or may not be FDA approved to treat the relevant
573 symptom [143].

574 Separate and apart from the potential benefit of psychotropic benefits when used as
575 psychotropics, some also have some antimicrobial and immune effects [145].

576 When the symptoms are caused by persistent relapsing infection, antibiotic treatment late in
577 the course of the illness may prevent some further neuropsychiatric disease progression but
578 may be unable to reverse all the previously established neuropsychiatric impairments. Since
579 our current technological limitations prevent us from being sure all tick-borne infections
580 have been eradicated, after stabilization constant vigilance is needed to recognize a possible
581 relapse that may require further treatment [143].

582 **Conclusion**

583 Infections, tick-borne infections and persistent complex interactive infections with
584 associated immune evasion and suppression in the body can cause acute and chronic
585 immune effects and biochemical changes in the brain causing neuropsychiatric symptoms.
586 The sleep disorders and chronic unremitting stress associated with these impairments
587 contribute to further disease progression of neuropsychiatric disorders. The pathological
588 effects of these processes result in developmental disorders, autism spectrum disorders,
589 schizoaffective disorders, bipolar disorder, depression, anxiety disorders (panic disorder,
590 social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder, intrusive
591 symptoms), eating disorders, sleep disorders, decreased libido, addiction, opioid addiction,
592 cognitive impairments, dementia, seizure disorders, suicide, violence, anhedonia,
593 depersonalization, dissociative episodes, derealization and other impairments. Prior studies
594 looked mostly at the prevalence of neuropsychiatric impairments following Lyme
595 borreliosis/tick-borne disease infections, but future studies are needed to look more at the
596 prevalence of these infections in patients with identified neuropsychiatric impairments.
597 Diagnosis of LB/TBD cases can be facilitated by a screening assessment followed by a
598 comprehensive psychiatric clinical exam relevant to patient's complaints and findings with
599 a through history, mental status exam, review of systems, neurological exam, physical
600 exam, a knowledgeable interpretation of laboratory findings, pattern recognition and
601 clinical judgment are helpful.

602 Treatment approaches that reduce symptoms that contribute to disease progression (sleep
603 disorders, fatigue, cognitive impairments, depression anxiety disorders, chronic pain) in
604 combination with antimicrobial and other treatments can be beneficial.

605 Sir William Osler, the father of American Medicine said— “He who knows syphilis knows
606 medicine.” It can now be said—He who knows Lyme disease knows medicine, neurology,
607 psychiatry, immunology, psychoimmunology, neurochemistry, ecology, law, politics, and
608 ethics.

609 Awareness of the association between Lyme borreliosis/tick-borne diseases and
610 neuropsychiatric impairments and studies of their prevalence in neuropsychiatric conditions
611 can improve understanding of the causes of mental illness and violence and result in more
612 effective prevention, diagnosis and treatment.

613 **Acknowledgments:** The author would like to acknowledge the contributions from all
614 his patients who provided a description and insight about their illness that will educate and
615 help others.

616 **Conflicts of Interest:** The authors declare no conflict of interest.

617

618

619 **References**

¹ Smith A, Oertle J, Warren D, Prato D. Chronic Lyme disease complex and its commonly undiagnosed primary and secondary co-infections. *Open Journal of Medical Microbiology*. 2015;5(3). DOI:[10.4236/ojmm.2015.53018](https://doi.org/10.4236/ojmm.2015.53018)

² Bransfield RC. List of 700 articles citing chronic infection associated with tick-borne diseases compiled by Dr. Robert Bransfield. ILADS. 2015. Available online at: http://www.ilads.org/ilads_news/wp-content/uploads/2017/02/CLDList-ILADS.pdf. Accessed May 26, 2018.

³ *Diagnostic and statistical manual of mental disorders* (5th ed.). American Psychiatric Association. American Psychiatric Publishing. Arlington, VA, USA. 2013.

⁴ Gammelgaard A. Evolutionary biology and the concept of disease. *Med Health Care Philos*. 2000;3(2):109-16.

⁵ O'Connor SM, Taylor CE, Hughes JM. Emerging infectious determinants of chronic diseases. *Emerg Infect Dis*. 2006 Jul;12(7):1051-7.

⁶ Kramer P, Bressan P. Humans as Superorganisms: How Microbes, Viruses, Imprinted Genes, and Other Selfish Entities Shape Our Behavior. *Perspect Psychol Sci*. 2015 Jul;10(4):464-81. doi: [10.1177/1745691615583131](https://doi.org/10.1177/1745691615583131).

⁷ Bransfield RC. Preventable cases of autism: Relationship between chronic infectious diseases and neurological outcome. *Pediatric Health*. 2009;3(2):125-140.

⁸ Bransfield RC. Lyme Disease, Comorbid Tick-Borne Diseases, and Neuropsychiatric Disorders. *Psychiatric Times*. 2007 Dec; 24(14):59-61. Available online at: <http://www.psychiatristimes.com/major-depressive-disorder/lyme-disease-comorbid-tick-borne-diseases-and-neuropsychiatric-disorders> Accessed May 26, 2018.

-
- ⁹ Fallon BA, Nields JA, Burrascano JJ, Liegner K, DelBene D, Liebowitz MR. The neuropsychiatric manifestations of Lyme borreliosis. *Psychiatr Q.* 1992 Spring;63(1):95-117.
- ¹⁰ Fallon BA, Nields JA. Lyme disease: a neuropsychiatric illness. *Am J Psychiatry.* 1994 Nov;151(11):1571-83.
- ¹¹ Fallon BA, Kochevar JM, Gaito A, Nields JA. The underdiagnosis of neuropsychiatric Lyme disease in children and adults. *Psychiatr Clin North Am.* 1998 Sep;21(3):693-703, viii.
- ¹² Bransfield RC. Aggressiveness, violence, homicidality, homicide, and Lyme disease. *Neuropsychiatr Dis Treat.* 2018 Mar 9;14:693-713. doi: 10.2147/NDT.S155143.
- ¹³ Chung Y, Zhang N, Wooten RM. *Borrelia burgdorferi* elicited-IL-10 suppresses the production of inflammatory mediators, phagocytosis, and expression of co-stimulatory receptors by murine macrophages and/or dendritic cells. *PLoS One.* 2013 Dec 19;8(12):e84980. doi: 10.1371/journal.pone.0084980.
- ¹⁴ Elsner RA, Hastey CJ, Olsen KJ, Baumgarth N. Suppression of Long-Lived Humoral Immunity Following *Borrelia burgdorferi* Infection. *PLoS Pathog.* 2015 Jul 2;11(7):e1004976. doi: 10.1371/journal.ppat.1004976.
- ¹⁵ Embers ME, Ramamoorthy R, Philipp MT. Survival strategies of *Borrelia burgdorferi*, the etiologic agent of Lyme disease. *Microbes Infect.* 2004 Mar;6(3):312-8. Review.
- ¹⁶ Hastey CJ, Elsner RA, Barthold SW, Baumgarth N. Delays and diversions mark the development of B cell responses to *Borrelia burgdorferi* infection. *J Immunol.* 2012 Jun 1;188(11):5612-22. doi: 10.4049/jimmunol.1103735.
- ¹⁷ Berndtson K. Review of evidence for immune evasion and persistent infection in Lyme disease. *Int J Gen Med.* 2013 Apr 23;6:291-306. doi: 10.2147/IJGM.S44114.
- ¹⁸ Miklossy J. Chronic or late Lyme neuroborreliosis: analysis of evidence compared to chronic or late neurosyphilis. *Open Neurol J.* 2012;6:146-57. doi: 10.2174/1874205X01206010146.
- ¹⁹ Back T, Grünig S, Winter Y, Bodechtel U, Guthke K, Khati D, von Kummer R. Neuroborreliosis-associated cerebral vasculitis: long-term outcome and health-related quality of life. *J Neurol.* 2013 Jun;260(6):1569-75. doi: 10.1007/s00415-013-6831-4.
- ²⁰ Bransfield RC. The Psychoimmunology of Lyme/Tick-Borne Diseases and its Association with Neuropsychiatric Symptoms. *Open Neurol J.* 2012;688-93. doi: 10.2174/1874205X01206010088.
- ²¹ Fallon BA, Levin ES, Schweitzer PJ, Hardesty D. Inflammation and central nervous system Lyme disease. *Neurobiol Dis.* 2010 Mar;37(3):534-41. doi: 10.1016/j.nbd.2009.11.016.
- ²² Aucott JN, Soloski MJ, Rebman AW, Crowder LA, Lahey LJ, Wagner CA, Robinson WH, Bechtold KT. CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study. *Clin Vaccine Immunol.* 2016 Sep 6;23(9):757-66. doi: 10.1128/CVI.00071-16.
- ²³ Bransfield RC. Inflammation and Autoimmunity in Lyme Disease and Psychiatric Sequellae. *Psychiatric Annals.* 2012; 42(9):337-341.
- ²⁴ Ramesh G, Didier PJ, England JD, Santana-Gould L, Doyle-Meyers LA, Martin DS, Jacobs MB, Philipp MT. Inflammation in the pathogenesis of Lyme neuroborreliosis. *Am J Pathol.* 2015 May;185(5):1344-60.
- ²⁵ Wichers MC, Koek GH, Robaey G, Verkerk R, Scharpé S, Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. *Mol Psychiatry.* 2005 Jun;10(6):538-44.

-
- ²⁶ Halperin JJ, Heyes MP. Neuroactive kynurenines in Lyme borreliosis. *Neurology*. 1992 Jan;42(1):43-50.
- ²⁷ Shimamoto Y, Sasaki M, Ikadai H, Ishizuka M, Yokoyama N, Igarashi I, Hoshi F, Kitamura H. Downregulation of hepatic cytochrome P450 3A in mice infected with *Babesia microti*. *J Vet Med Sci*. 2012 Feb;74(2):241-5.
- ²⁸ Maritsi DN, Zarganis D, Metaxa Z, Papaioannou G, Vartzelis G. Bartonella henselae Infection: An Uncommon Mimicker of Autoimmune Disease. *Case Rep Pediatr*. 2013;2013:726826. doi: 10.1155/2013/726826.
- ²⁹ Jarefors S, Karlsson M, Forsberg P, Eliasson I, Ernerudh J, Ekerfelt C. Reduced number of interleukin-12 secreting cells in patients with Lyme borreliosis previously exposed to *Anaplasma phagocytophilum*. *Clin Exp Immunol*. 2006 Feb;143(2):322-8.
- ³⁰ Grab DJ, Nyarko E, Barat NC, Nikolskaia OV, Dumler JS. *Anaplasma phagocytophilum*-*Borrelia burgdorferi* coinfection enhances chemokine, cytokine, and matrix metalloprotease expression by human brain microvascular endothelial cells. *Clin Vaccine Immunol*. 2007 Nov;14(11):1420-4.
- ³¹ Meyer Sauter PM, Streuli JC, Iff T, Goetschel P. Mycoplasma pneumoniae-associated encephalitis in childhood--nervous system disorder during or after a respiratory tract infection. *Klin Padiatr*. 2011 Jul;223(4):209-13. doi: 10.1055/s-0031-1271717.
- ³² Harley JB, Chen X, Pujato M, Miller D, Maddox A, Forney C, Magnusen AF, Lynch A, Chetal K, Yukawa M, Barski A, Salomonis N, Kaufman KM, Kottyan LC, Weirauch MT. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. *Nat Genet*. 2018 May;50(5):699-707. doi: 10.1038/s41588-018-0102-3.
- ³³ Greenberg HE, Ney G, Scharf SM, Ravdin L, Hilton E. Sleep quality in Lyme disease. *Sleep*. 1995 Dec;18(10):912-6.
- ³⁴ Kelley KW. The role of growth hormone in modulation of the immune response. *Ann N Y Acad Sci*. 1990;594:95-103.
- ³⁵ Benedict C, Cedernaes J, Giedraitis V, Nilsson EK, Hogenkamp PS, Vågesjö E, Massena S, Pettersson U, Christofferson G, Phillipson M, Broman JE, Lannfelt L, Zetterberg H, Schiöth HB. Acute sleep deprivation increases serum levels of neuron-specific enolase (NSE) and S100 calcium binding protein B (S-100B) in young men. *Sleep*. 2014 Jan 1;37(1):195-8. doi: 10.5665/sleep.3336.
- ³⁶ Zhang J, Zhu Y, Zhan G, Fenik P, Panossian L, Wang MM, Reid S, Lai D, Davis JG, Baur JA, Veasey S. Extended wakefulness: compromised metabolics in and degeneration of locus ceruleus neurons. *J Neurosci*. 2014 Mar 19;34(12):4418-31. doi: 10.1523/JNEUROSCI.5025-12.2014.
- ³⁷ Lorton D, Lubahn CL, Estus C, Millar BA, Carter JL, Wood CA, Bellinger DL. Bidirectional communication between the brain and the immune system: implications for physiological sleep and disorders with disrupted sleep. *Neuroimmunomodulation*. 2006;13(5-6):357-74.
- ³⁸ Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid β -amyloid 42 in healthy middle-aged men: a randomized clinical trial. *JAMA Neurol*. 2014 Aug;71(8):971-7. doi: 10.1001/jamaneurol.2014.1173.
- ³⁹ Bransfield RC. Lyme borreliosis and mental illness: past, present and future. Proceedings of European Lyme Borreliosis Conference. April 28, 2018. Villach Austria.
- ⁴⁰ Hájek T, Pasková B, Janovská D, Bahbouh R, Hájek P, Libiger J, Höschl C. Higher prevalence of antibodies to *Borrelia burgdorferi* in psychiatric patients than in healthy subjects. *Am J Psychiatry*. 2002 Feb;159(2):297-301.

-
- ⁴¹ Greenberg R. Aggressiveness, violence, homicidality, homicide, and Lyme disease. Letter to the editor. 2018. May 14;14:1253-1254. doi: <https://doi.org/10.2147/NDT.S168751>
- ⁴² Bransfield RC. Suicide and Lyme and associated diseases. *Neuropsychiatr Dis Treat*. 2017 Jun 16;13:1575-1587. doi: 10.2147/NDT.S136137.
- ⁴³ Luché-Thayer J, Ahern H, DellaSala D, Franklin S, Gilbert L, Horowitz R, Liegner K, McManus M, Meseko C, Miklossy J, Rudenko N, Stuckelberger A. *Updating ICD11 Borreliosis Diagnostic Codes: Edition One*. CreateSpace Independent Publishing Platform. North Charleston, NC, USA. 2017. ISBN-10: 1978091796 ISBN-13: 978-1978091795.
- ⁴⁴ Oksi J, Kalimo H, Marttila RJ, Marjamäki M, Sonninen P, Nikoskelainen J, Viljanen MK. Inflammatory brain changes in Lyme borreliosis. A report on three patients and review of literature. *Brain*. 1996 Dec;119 (Pt 6):2143-54.
- ⁴⁵ Schlesinger PA, Duray PH, Burke BA, Steere AC, Stillman MT. Maternal-fetal transmission of the Lyme disease spirochete, *B. burgdorferi*. *Ann Intern Med*. 1985;103(1):67-8.
- ⁴⁶ MacDonald AB. Gestational Lyme borreliosis. Implications for the fetus. *Rheum Dis Clin North Am*. 1989;15(4):657-77.
- ⁴⁷ Harvey WT, Salvato P. 'Lyme disease': ancient engine of an unrecognized borreliosis pandemic? *Med Hypotheses*. 2003 May;60(5):742-59.
- ⁴⁸ Breitschwerdt EB, Maggi RG, Farmer P, Mascarelli PE. Molecular evidence of perinatal transmission of *Bartonella vinsonii* subsp. *berkhoffii* and *Bartonella henselae* to a child. *J Clin Microbiol*. 2010;48(6):2289-93.
- ⁴⁹ Faber S. *32 Years of Documentation of Maternal-Child Transmission of Lyme Disease and Congenital Lyme Borreliosis 2018*. Available online at: <http://www.lymehope.ca/advocacy-updates/march-03rd-2018> Accessed May 28, 2018.
- ⁵⁰ Gardner, T. Lyme disease. In: Remington JK, J. editor. *Infectious Diseases of the Fetus and Newborn, 5th ed*: Saunders; 2001. Philadelphia, PA, USA.
- ⁵¹ Jones CR, Smith H, Gibb E, Johnson L. Gestational Lyme Disease Case studies of 102 Live Births. *Lyme Times*. 2005:34–6. Summer.
- ⁵² Bransfield RC, Wulfman JS, Harvey WT, Usman AI. The association between tick-borne infections, Lyme borreliosis and autism spectrum disorders. *Med Hypotheses*. 2008;70(5):967-74.
- ⁵³ Bransfield RC, Fallon BA, Raxlen B, Shepler L, Sherr VT. A Modest Proposal. *Psychiatric News*. 1998; 31(18):16.
- ⁵⁴ Nicolson GL, Gan R, Nicolson NL, Haier J. Evidence for *Mycoplasma*, *Chlamydia pneumoniae* and HHV-6 Co-infections in the blood of patients with Autism Spectrum Disorders. *J Neuroscience Res*. 2007;85:11431148.
- ⁵⁵ Nicolson G. Haier J. Role of Chronic bacterial and viral infections in neurodegenerative, neurobehavioral, psychiatric, autoimmune and fatiguing illnesses: part 1. *BJMP* 2009;2(4) 20-28.
- ⁵⁶ Vojdani A. Antibodies as predictors of complex autoimmune diseases and cancer. *Int J Immunopathol Pharmacol*. 2008; 21(3):553-66.
- ⁵⁷ Bransfield R. Chronic infections contributing to autism spectrum disorders. *Neurology Psychiatry & Brain Research*. Universitätsverlag. Heidelberg. 2009; 16, Suppl 1
- ⁵⁸ Bransfield RC, Kuhn M. Autism and Lyme disease. *JAMA*. 2013 Aug 28;310(8):856-7. doi: 10.1001/jama.2013.194747.
- ⁵⁹ Alonso L, Raymond P. Complex Chronic Infections in Autistic Children. Proceedings of ILADS 2017 European Conference. May 19, 2017, Paris, France.

-
- ⁶⁰ Kucharska, M. Child with autism, Mother with Lyme - Congenital Borreliosis? Proceedings of 18th Annual ILADS Scientific Conference. Nov 9-12, 2017, Boston, MA, USA.
- ⁶¹ Kuhn M, Bransfield R. Divergent opinions of proper Lyme disease diagnosis and implications for children co-morbid with autism spectrum disorder. *Med Hypotheses*. 2014 Sep;83(3):321-5. doi: 10.1016/j.mehy.2014.06.005.
- ⁶² Kuhn M, Grave S, Bransfield R, Harris S. Long term antibiotic therapy may be an effective treatment for children co-morbid with Lyme disease and autism spectrum disorder. *Med Hypotheses*. 2012 May;78(5):606-15. doi: 10.1016/j.mehy.2012.01.037.
- ⁶³ Fellerhoff B, Wank R. Increased prevalence of Chlamydothila DNA in post-mortem brain frontal cortex from patients with schizophrenia. *Schizophr Res*. 2011 Jul;129(2-3):191-5. doi: 10.1016/j.schres.2011.04.015.
- ⁶⁴ Hess A, Buchmann J, Zetl UK, Henschel S, Schlaefke D, Grau G, Benecke R. Borrelia burgdorferi central nervous system infection presenting as an organic schizophrenialike disorder. *Biol Psychiatry*. 1999 Mar 15;45(6):795.
- ⁶⁵ Brown JS Jr. Geographic correlation of schizophrenia to ticks and tick-borne encephalitis. *Schizophr Bull*. 1994;20(4):755-75.] <https://doi.org/10.1093/schbul/20.4.755>
- ⁶⁶ Mattingley DW, Koola MM. Association of Lyme disease and schizoaffective disorder, bipolar type: is it inflammation mediated? *Indian J Psychol Med*. 2015 Apr-Jun;37(2):243-6.
- ⁶⁷ Roelcke U, Barnett W, Wilder-Smith E, Sigmund D, Hacke W. Untreated neuroborreliosis: Bannwarth's syndrome evolving into acute schizophrenia-like psychosis. A case report. *J Neurol*. 1992 Mar;239(3):129-31.
- ⁶⁸ Bär KJ, Jochum T, Häger F, Meissner W, Sauer H. Painful hallucinations and somatic delusions in a patient with the possible diagnosis of neuroborreliosis. *Clin J Pain*. 2005 Jul-Aug;21(4):362-3.
- ⁶⁹ Császár T, Patakfalvi A. [Differential diagnostic problems in Lyme disease (Borrelia infection resulting in acute exogenous psychosis)]. *Orv Hetil*. 1994 Oct 9;135(41):2269-71. Hungarian.
- ⁷⁰ Barnett W, Sigmund D, Roelcke U, Mundt C. [Endogenous paranoid-hallucinatory syndrome caused by Borrelia encephalitis]. *Nervenarzt*. 1991 Jul;62(7):445-7. German.
- ⁷¹ van den Bergen HA, Smith JP, van der Zwan A. [Lyme psychosis]. *Ned Tijdschr Geneesk*. 1993 Oct 9;137(41):2098-100. Dutch.
- ⁷² Markeljević J, Sarac H, Rados M. Tremor, seizures and psychosis as presenting symptoms in a patient with chronic Lyme neuroborreliosis (LNB). *Coll Antropol*. 2011 Jan;35 Suppl 1:313-8.
- ⁷³ Fallon BA, Niels JA, Parsons B, Liebowitz MR, Klein DF. Psychiatric manifestations of Lyme borreliosis. *J Clin Psychiatry*. 1993 Jul;54(7):263-8.
- ⁷⁴ Scheffer RE, Linden S. Concurrent medical conditions with pediatric bipolar disorder. *Curr Opin Psychiatry*. 2007 Jul;20(4):398-401.
- ⁷⁵ Greenberg R. Infections and Childhood Psychiatric Disorders: Tick-Borne Illness and Bipolar Disorder in Youth. *Bipolar Disord*. 2017, 3:1. doi: 10.4172/2472-1077.1000113
- ⁷⁶ Lobraico J, Butler A, Petrini J, Ahmadi R. New insights into stages of Lyme disease symptoms from a novel hospital-based registry. *J Prim Care Community Health*. 2014 Oct;5(4):284-7. doi: 10.1177/2150131914540693.
- ⁷⁷ Aucott JN, Rebman AW, Crowder LA, Kortte KB. Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here? *Qual Life Res*. 2013;22(1):75-84.

-
- ⁷⁸ Tager FA, Fallon BA, Keilp J, Rissenberg M, Jones CR, Liebowitz MR. A controlled study of cognitive deficits in children with chronic Lyme disease. *J Neuropsychiatry Clin Neurosci*. 2001 Fall;13(4):500-7.
- ⁷⁹ Bransfield RC. Intrusive symptoms and infectious encephalopathies. *Neurol Psychiatry Brain Res*. 2016;22:3-4.
- ⁸⁰ Oczko-Grzesik B, Kępa L, Puszcz-Matlińska M, Pudło R, Żurek A, Badura-Głębik T. Estimation of cognitive and affective disorders occurrence in patients with Lyme borreliosis. *Ann Agric Environ Med*. 2017;24(1):33-38.
- ⁸¹ Gustaw K, Beltowska K, Studzińska MM. Neurological and psychological symptoms after the severe acute neuroborreliosis. *Ann Agric Environ Med*. 2001;8(1):91-94.
- ⁸² Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. *N Engl J Med*. 1990 Nov 22;323(21):1438-44.
- ⁸³ Shea L. Psychological Symptoms in Children with Lyme Disease. Presented at: Challenges and Controversy in Lyme Disease and Tick Borne Illness Care Symposium, Massachusetts General Hospital. November 9, 2013. Boston, MA, USA.
- ⁸⁴ Fallon BA, Nields JA, Parsons B, Liebowitz MR, Klein DF. Psychiatric manifestations of Lyme borreliosis. *J Clin Psychiatry*. 1993 Jul;54(7):263-8.
- ⁸⁵ Garakani A, Mitton AG. New-onset panic, depression with suicidal thoughts, and somatic symptoms in a patient with a history of Lyme disease. *Case Rep Psychiatry*. 2015;2015:457947. doi: 10.1155/2015/457947.
- ⁸⁶ Sherr VT. Panic attacks may reveal previously unsuspected chronic disseminated Lyme disease. *J Psychiatr Pract*. 2000 Nov;6(6):352-6.
- ⁸⁷ Bär KJ, Jochum T, Häger F, Meissner W, Sauer H. Painful hallucinations and somatic delusions in a patient with the possible diagnosis of neuroborreliosis. *Clin J Pain*. 2005 Jul-Aug;21(4):362-3.
- ⁸⁸ Schaller JL, Burkland GA, Langhoff PJ. Do bartonella infections cause agitation, panic disorder, and treatment-resistant depression? *MedGenMed*. 2007 Sep 13;9(3):54.
- ⁸⁹ Rhee H, Cameron DJ. Lyme disease and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS): an overview. *Int J Gen Med*. 2012;5:163-74. doi: 10.2147/IJGM.S24212.
- ⁹⁰ Leonard HL, Swedo SE. Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS). *Int J Neuropsychopharmacol*. 2001 Jun;4(2):191-8.
- ⁹¹ Schneider RK, Robinson MJ, Levenson JL. Psychiatric presentations of non-HIV infectious diseases. Neurocysticercosis, Lyme disease, and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection. *Psychiatr Clin North Am*. 2002 Mar;25(1):1-16.
- ⁹² Johnco C, Kugler BB, Murphy TK, Storch EA. Obsessive-compulsive symptoms in adults with Lyme disease. *Gen Hosp Psychiatry*. 2018 Mar - Apr;51:85-89. doi: 10.1016/j.genhosppsy.2018.01.009.
- ⁹³ Nields JA, Fallon BA, Jastreboff PJ. Carbamazepine in the treatment of Lyme disease-induced hyperacusis. *J Neuropsychiatry Clin Neurosci*. 1999 Winter;11(1):97-9.
- ⁹⁴ Posttraumatic Stress Disorder & infectious Encephalopathies. Spotlight Nov/Dec 2001. Available online at: <http://www.mentalhealthandillness.com/lymeframes.html> Accessed May 28, 2018.
- ⁹⁵ Dupuis MJ. [Multiple neurologic manifestations of *Borrelia burgdorferi* infection]. *Rev Neurol (Paris)*. 1988;144(12):765-75.

-
- ⁹⁶ Raven N. Bicycle boy. *The Washingtonian*. Jan. 1991.
- ⁹⁷ Stahl, M, Fressle, R, Wilske, B. Lyme neuroborreliosis presenting as *anorexia nervosa*. *Münchener Medizinische Wochenschrift*. 1990;132(40):615-619
- ⁹⁸ van Nunen SA. Tick-induced allergies: mammalian meat allergy and tick anaphylaxis. *Med J Aust*. 2018 Apr 16;208(7):316-321.
- ⁹⁹ Parish JM. Sleep-related problems in common medical conditions. *Chest*. 2009 Feb;135(2):563-572. doi: 10.1378/chest.08-0934.
- ¹⁰⁰ Steffen A, Hagenah J, Wollenberg B, Brüggemann N. A case of central sleep apnea strictly dependent upon REM-sleep. *J Neurol*. 2010 Jan;257(1):143-5.
- ¹⁰¹ Stein SL, Solvason HB, Biggart E, Spiegel D. A 25-year-old woman with hallucinations, hypersexuality, nightmares, and a rash. *Am J Psychiatry*. 1996 Apr;153(4):545-51.
- ¹⁰² Fine EJ. The Alice in Wonderland syndrome. *Prog Brain Res*. 2013;206:143-56. doi: 10.1016/B978-0-444-63364-4.00025-9.
- ¹⁰³ Savvidou A, Knudsen S, Olsson-Engman M, Gammeltoft S, Jennum P, Palm L. Hypocretin deficiency develops during onset of human narcolepsy with cataplexy. *Sleep*. 2013 Jan 1;36(1):147-8. doi: 10.5665/sleep.2320.
- ¹⁰⁴ Askenazy F, Dor E, Benoit M, Dupuis G, Serret S, Myquel M, Seddiki Y.[Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up]. *Encephale*. 2010 Feb;36(1):46-53. doi: 10.1016/j.encep.2009.01.006.
- ¹⁰⁵ Silva MT, Sophar M, Howard RS, Spencer GT. Neuroborreliosis as a cause of respiratory failure. *J Neurol*. 1995 Sep;242(9):604-7.
- ¹⁰⁶ Hemmer B, Riemann D, Glocker FX, Lücking CH, Deuschl G. Restless legs syndrome after a borrelia-induced myelitis. *Mov Disord*. 1995 Jul;10(4):521-2.
- ¹⁰⁷ Weinstein ER, Rebman AW, Aucott JN, Johnson-Greene D, Bechtold KT. Sleep quality in well-defined Lyme disease: a clinical cohort study in Maryland. *Sleep*. 2018 May 1;41(5). doi: 10.1093/sleep/zsy035.
- ¹⁰⁸ Bransfield RC. Sleep disorders impacting Lyme patients. Proceedings of 15th Annual ILADS Scientific Conference. October 10, 2014. Washington DC, USA.
- ¹⁰⁹ Bransfield RC. Sleep disorders impacting Lyme disease Patients. John Drulle, MD Memorial Lecture. Proceedings of 17th Annual ILADS Scientific Conference. November 6, 2016. Philadelphia, PA, USA.
- ¹¹⁰ Johnson L, Wilcox S, Mankoff J, Stricker RB. Severity of chronic Lyme disease compared to other chronic conditions: a quality of life survey. *PeerJ*. 2014 Mar 27;2:e322. doi: 10.7717/peerj.322.
- ¹¹¹ Saito K, Takanishi T, Okuda Y, Kitajima T. [Long-term administration of large doses of oral morphine for chronic pain]. *Masui*. 1998 Jun;47(6):749-50. Japanese.
- ¹¹² Hanna AF, Abraham B, Hanna A, Smith AJ. Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome. *Int Med Case Rep J*. 2017 Aug 18;10:305-308. doi: 10.2147/IMCRJ.S137975.
- ¹¹³ Davis MA, Lin LA, Liu H, Sites BD. Prescription Opioid Use among Adults with Mental Health Disorders in the United States. *J Am Board Fam Med*. 2017 Jul-Aug;30(4):407-417. doi: 10.3122/jabfm.2017.04.170112.

-
- ¹¹⁴ Blum K, Modestino EJ, Febo M, Steinberg B, McLaughlin T, Fried L, Baron D, Siwicki D, Badgaiyan RD. Lyme and Dopaminergic Function: Hypothesizing Reduced Reward Deficiency Symptomatology by Regulating Dopamine Transmission. *J Syst Integr Neurosci*. 2017 May;3(3). doi: 10.15761/JSIN.1000163.
- ¹¹⁵ Chabria S, Ogbuagu O. Fatal multiple deer tick-borne infections in an elderly patient with advanced liver disease. *BMJ Case Rep*. 2015 Mar 2;2015. pii:bcr2014208182. doi: 10.1136/bcr-2014-208182.
- ¹¹⁶ Gheorghiev C, De Montleau F, Defuentes G. [Alcohol and epilepsy: a case report between alcohol withdrawal seizures and neuroborreliosis]. *Encephale*. 2011 Jun;37(3):231-7. doi: 10.1016/j.encep.2010.10.004.
- ¹¹⁷ Beuselinc B, Willems R. Think outside the heart! Case report of Lyme disease. *Acta Cardiol*. 2007 Oct;62(5):519-22.
- ¹¹⁸ Cuglituri G, Maggioli G. [Biliary lithogenic factors in the course of alcoholic liver cirrhosis]. *Minerva Dietol Gastroenterol*. 1990 Apr-Jun;36(2):91-3. Italian.
- ¹¹⁹ Staff. In NY follow-up letter, Dr. Bransfield connects Lyme to opioid crisis. LymeDisease.org. Sept 6, 2017. Available online at: https://www.lymedisease.org/bransfield-lyme-opioid-crisis/?utm_source=sept+9--sleeper&utm_campaign=sept+5--sleeper+cells&utm_medium=email accessed May 28, 2018.
- ¹²⁰ Bransfield RC. Intrusive Symptoms, Post-Traumatic Stress Disorder and Addictive Disorders in Lyme/Tick-Borne Diseases. Proceedings of 15th Annual ILADS Scientific Conference. October 9, 2014. Washington DC, USA.
- ¹²¹ Benke T, Gasse T, Hittmair-Delazer M, Schmutzhard E. Lyme encephalopathy: long-term neuropsychological deficits years after acute neuroborreliosis. *Acta Neurol Scand*. 1995 May;91(5):353-7.
- ¹²² Bransfield RC. Lyme Disease and Cognitive Impairments. Science Research. 2008; August 8. Available online at: <http://www.publichealthalert.org/lyme-disease-and-cognitive-impairments.html> Accessed May 28 Accessed May 28, 2018.
- ¹²³ Patrick McAuliffe, Marla R. Brassard & Brian Fallon (2010) Memory and Executive Functions in Adolescents with Posttreatment Lyme Disease. *Applied Neuropsychology*. 15:3, 208-219, doi: [10.1080/09084280802324473](https://doi.org/10.1080/09084280802324473)
- ¹²⁴ Kaplan RF, Meadows ME, Vincent LC, Logigian EL, Steere AC. Memory impairment and depression in patients with Lyme encephalopathy: comparison with fibromyalgia and nonpsychotically depressed patients. *Neurology*. 1992 Jul;42(7):1263-7.
- ¹²⁵ Stricker RB, Winger EE. Musical hallucinations in patients with Lyme disease. *South Med J*. 2003 Jul;96(7):711-5.
- ¹²⁶ Keilp JG, Corbera K, Slavov I, Taylor MJ, Sackeim HA, Fallon BA. WAIS-III and WMS-III performance in chronic Lyme disease. *J Int Neuropsychol Soc*. 2006 Jan;12(1):119-29.
- ¹²⁷ Molrine CJ. The Experience of Lyme Disease: Cognitive-Communicative Symptomatology. Proceedings of Drexel University ILADS Conference. April 10, 2015. Philadelphia, PA, USA.
- ¹²⁸ Miklossy J. Chronic or late Lyme neuroborreliosis: analysis of evidence compared to chronic or late neurosyphilis. *Open Neurol J*. 2012;6:146-57. doi: 10.2174/1874205X01206010146.

-
- ¹²⁹ Back T, Grünig S, Winter Y, Bodechtel U, Guthke K, Khati D, von Kummer R. Neuroborreliosis-associated cerebral vasculitis: long-term outcome and health-related quality of life. *J Neurol*. 2013 Jun;260(6):1569-75. doi: 10.1007/s00415-013-6831-4.
- ¹³⁰ Waniek C, Prohovnik I, Kaufman MA, Dwork AJ. Rapidly progressive frontal-type dementia associated with Lyme disease. *J Neuropsychiatry Clin Neurosci*. 1995 Summer;7(3):345-7.
- ¹³¹ Bransfield RC. Case Report: Lyme Disease and Complex Seizures. *Journal of Spirochetes and Tick-borne Diseases*. 1999 Fall/Winter 1999;6:123-125.
- ¹³² Markeljević J, Sarac H, Rados M. Tremor, seizures and psychosis as presenting symptoms in a patient with chronic Lyme neuroborreliosis. *Coll Antropol*. 2011 Jan;35 Suppl 1:313-8.
- ¹³³ Bloom BJ, Wyckoff PM, Meissner HC, Steere AC. Neurocognitive abnormalities in children after classic manifestations of Lyme disease. *Pediatr Infect Dis J*. 1998 Mar;17(3):189-96.
- ¹³⁴ Eskow E, Rao RV, Mordechai E. Concurrent infection of the central nervous system by *Borrelia burgdorferi* and *Bartonella henselae*: evidence for a novel tick-borne disease complex. *Arch Neurol*. 2001 Sep;58(9):1357-63.
- ¹³⁵ Brogan GX, Homan CS, Viccellio P. The enlarging clinical spectrum of Lyme disease: Lyme cerebral vasculitis, a new disease entity. *Ann Emerg Med*. 1990 May;19(5):572-6.
- ¹³⁶ Rothaus C. A girl with seizures. *Now @ NEJM*. 2015 May 22. Available online at: <http://blogs.nejm.org/now/index.php/a-girl-with-seizures/2015/05/22/comment-page-1/#comment-225701> Accessed May 28, 2018.
- ¹³⁷ Bransfield RC. A structured clinical interview when neuropsychiatric Lyme disease is a possibility. Proceedings of LDF's 10th Annual International Scientific Conference on Lyme Borreliosis and Other Tick-borne Disorders; April 28, 1997. Bethesda, MD, USA.
- ¹³⁸ Bransfield RC. The neuropsychiatric assessment of Lyme disease. 1996. Available from: <http://www.mentalhealthandillness.com/lymeframes.html> Accessed May 28, 2018.
- ¹³⁹ Bransfield RC. The neuropsychiatric assessment of Lyme disease by the primary care physician. Proceedings of the 11th Annual International Scientific Conference on Lyme Disease & Other Spirochetal and Tick-borne Disorders; April 25, 1998; New York, NY, USA.
- ¹⁴⁰ Stricker RB, Johnson L. Lyme disease diagnosis and treatment: lessons from the AIDS epidemic. *Minerva Med*. 2010;101(6):419-425.
- ¹⁴¹ Cook MJ, Puri BK. Application of Bayesian decision-making to laboratory testing for Lyme disease and comparison with testing for HIV. *Int J Gen Med*. 2017;10:113-123.
- ¹⁴² Schutzer SE, Angel TE, Liu T, Schepmoes AA, Clauss TR, Adkins JN, Camp DG, Holland BK, Bergquist J, Coyle PK, Smith RD, Fallon BA, Natelson BH. Distinct cerebrospinal fluid proteomes differentiate post-treatment Lyme disease from chronic fatigue syndrome. *PLoS One*. 2011 Feb 23;6(2):e17287. doi: 10.1371/journal.pone.0017287.
- ¹⁴³ Bransfield R, Williams L. Psychopharmacological Treatments of Lyme and Tick-Borne Diseases. Proceedings of The ILADS 18th Annual Scientific Conference. November 10, 2017 Boston, MA, USA.
- ¹⁴⁴ Stricker RB, DeLong AK, Green CL, Savely VR, Chamallas SN, Johnson L. Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease. *Int J Gen Med*. 2011;4:639-46. doi: 10.2147/IJGM.S23829.

¹⁴⁵ Obregon D, Parker-Athill EC, Tan J, Murphy T. Psychotropic effects of antimicrobials and immune modulation by psychotropics: implications for neuroimmune disorders. *Neuropsychiatry* (London). 2012 Aug;2(4):331-343.